JP2003527414A - Drugs for treating hepatitis C - Google Patents
Drugs for treating hepatitis CInfo
- Publication number
- JP2003527414A JP2003527414A JP2001568401A JP2001568401A JP2003527414A JP 2003527414 A JP2003527414 A JP 2003527414A JP 2001568401 A JP2001568401 A JP 2001568401A JP 2001568401 A JP2001568401 A JP 2001568401A JP 2003527414 A JP2003527414 A JP 2003527414A
- Authority
- JP
- Japan
- Prior art keywords
- ukrain
- patients
- ifn
- hepatitis
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Abstract
(57)【要約】 C型肝炎を治療するための薬剤を製造するための、クサノオウのアルカロイドとチオリン酸トリアジリジドとの反応生成物の使用を開示している。 (57) [Summary] Disclosed is the use of the reaction product of celandine alkaloids and triaziridide thiophosphate for the manufacture of a medicament for treating hepatitis C.
Description
【0001】
本発明はC型肝炎を治療するための薬剤を製造するための、アルカロイドのリ
ン誘導体の使用に関する。The present invention relates to the use of phosphorus derivatives of alkaloids for the manufacture of a medicament for treating hepatitis C.
【0002】
C型肝炎という用語は、比較的最近になってから調査されている疾患の1つを
示している。長い間、これは従来公知の疾患であるA型肝炎およびB型肝炎と同
様の症状を惹起する疾患の1つであるが、その様相にある本質的な差異が存在す
ることだけが知られていた。したがって、この疾患はこれまで、「非A非B型肝
炎」の語で記載されてきた。The term hepatitis C refers to one of the diseases that has been investigated relatively recently. For a long time, this is one of the diseases causing similar symptoms to the conventionally known diseases, hepatitis A and hepatitis B, but it is known that there is an essential difference in its appearance. It was Therefore, this disease has previously been described in the term "non-A non-B hepatitis".
【0003】
C型肝炎は、特に先進国に広く拡がっている疾患であり、世界中で約1億70
00万人(即ちHIV感染の約4倍)がC型肝炎に感染していると推定される。Hepatitis C is a disease that is particularly widespread in developed countries, and is about 170 million worldwide.
It is estimated that one million people (ie, about four times HIV infection) are infected with hepatitis C.
【0004】
この間、C型肝炎ウイルスはフラビウイルス(flaviviridae)科
の群の1員であることを発見することができ、この疾患を予防または治療するた
めの薬剤を開発するための多大な努力が世界中でなされてきた。During this time, it was possible to discover that the hepatitis C virus is a member of the group of the flaviviridae family, and a great deal of effort has been devoted to developing drugs to prevent or treat this disease. It has been done all over the world.
【0005】
AT377988B号およびAT354644B号はそれぞれ、新規のアルカ
ロイドのリン誘導体および新規のチオリン酸のアルカロイド誘導体の塩を製造す
る方法を開示している。このような化合物は薬理活性を有し、細胞増殖抑制薬剤
として使用することができる。[0007] AT377988B and AT354644B respectively disclose processes for preparing new phosphorus derivatives of alkaloids and novel salts of alkaloid derivatives of thiophosphoric acid. Such compounds have pharmacological activity and can be used as cytostatic agents.
【0006】
意外にも、前記の特許明細書中に記載された物質のうちで特に、クサノオウ(
Chelidonium majus L.)のアルカロイドとチオリン酸トリ
アジリジドとの反応生成物はC型肝炎を治療するために使用することができ、こ
のような薬剤を用いると優れた結果を達成することができることが判明した。Surprisingly, among the substances described in the patent specifications mentioned above, the
Chelidonium majus L. It has been found that the reaction product of the alkaloids of)) with thiophosphoric acid triaziride can be used to treat hepatitis C, and excellent results can be achieved with such agents.
【0007】
したがって本発明は、C型肝炎を治療するための薬剤を製造するための、クサ
ノオウのアルカロイドとチオリン酸トリアジリジドとの反応生成物の使用に関す
る。The present invention therefore relates to the use of the reaction product of the alkaloids of Cercis chinensis and thiophosphoric acid triaziridide for the manufacture of a medicament for the treatment of hepatitis C.
【0008】
以下では前記の反応生成物を略称して「ウクライン(Ukrain)」と称す
る。ウクラインの主要な成分は次の式で示される。Hereinafter, the above-mentioned reaction product is abbreviated as “Ukrain”. The major components of Ukrain are given by the following formula.
【0009】[0009]
【化1】
一方ではインターフェロン−αと混合したウクラインを使用して、他方ではウ
クラインを単独で使用して試験を実施した。次にこの2つの一連の試験を記載す
る。[Chemical 1] The test was carried out using Ukrain mixed with interferon-α on the one hand and Ukrain alone on the other hand. The two series of tests are then described.
【0010】
1.インターフェロン−αおよびウクライン(Ukrain)の使用
方法
組換えヒトインターフェロン−α2b(IFN)およびウクライン(クサノオウ
−アルカロイドおよびチオリン酸トリアジリジドの半合成化合物、NSC−63
1570、「Nowicky Pharma」、オーストリア)の効果をインビ
トロで、血液のチオール−ジスルフィド比(SH/SS)(ロシア連邦特許21
50700号)に関して、電流滴定法で試験した。CHC患者40人を検査した
。IFNを用量20、50、100、200、400、600、1000U/血
液mlで、ウクラインを用量0.05、0.1、0.2、0.5、1.0および
2.0μg/血液mlで試験した。週3回の個々に最適なIFN用量(注射1回
当たり0.5から2.0MU(測定単位)、患者6人、HCV表現型laの3つ
のケースを含む)および隔日のウクライン用量(注射1回当たり0.25から2
.5mg、患者4人、HCVlbの2つのケースを含む)による臨床パイロット
試験のために、試験すべきCHC患者10人を選択した。1. Methods of Using Interferon-α and Ukrain Recombinant human interferon-α 2b (IFN) and Ukrain (a semi-synthetic compound of camphora-alkaloid and thiophosphoric acid triaziridide, NSC-63)
1570, "Nowicky Pharma", Austria), in vitro, blood thiol-disulfide ratio (SH / SS) (Russian Federal Patent 21).
50700) was tested by amperometric titration. 40 CHC patients were examined. IFN at doses of 20, 50, 100, 200, 400, 600, 1000 U / ml of blood and Ukrain at doses of 0.05, 0.1, 0.2, 0.5, 1.0 and 2.0 μg / ml of blood. Tested in. Individually optimal IFN dose three times weekly (including 0.5 to 2.0 MU (unit of measure) per injection, 6 patients, 3 cases of HCV phenotype la) and Ukrain dose every other day (1 injection 1 From 0.25 to 2 per session
. 10 CHC patients to be tested were selected for clinical pilot studies with 5 mg, 4 patients, including 2 cases of HCVlb).
【0011】
両方の組成物に対する反応は異なることが判明した。患者全員のうち52.5
%がIFNに対して感受性があり、73.1%がウクラインに対して感受性があ
り、その際、組成物の影響によるSH/SS比の上昇は、プラスの効果と考えら
れ、その低下はマイナスの効果と考えられる。一部の患者では、製剤の最初の投
与がすでにプラスの効果をもたらし、他の患者では、2回またはそれ以上の用量
を必要とした。より頻繁には、IFNに対する最適な生物学的応答が用量400
、200および100IU/血液mlで、ウクラインでは用量0.5、0.1お
よび0.2μg/血液mlで観察された。3.0から5.0MU用量のインビボ
注射に対応する600から1000IU/mlの標準化治療IFN用量は0から
18.2%のケースでのみSH/SSシステムに対してプラスの効果を示し、6
3.6から81.8%のケースでマイナスの効果を示し、これは、CHCにおけ
るIFNの乏しい効果およびIFN治療における副作用頻発の理由の1つである
。証明されたHCV表現型lbを伴う4つのケースを含めてCHC患者全員のう
ちのほぼ半数がIFNに対して耐性がある(47.5%)。IFNまたはウクラ
インでの個別の治療の後に、患者10人のうちの9人はPCRにおいてHCV−
RNA陰性であった。その内訳は、1ヵ月後に3人、単独IFN用量での治療3
ヶ月後に3人、ウクラインでの単独治療3週間後に3人である。重篤な副作用は
観察されず、患者全員の治療を続ける。It has been found that the response to both compositions is different. 52.5 of all patients
% Were sensitive to IFN and 73.1% were sensitive to Ukrain, in which case the increase in SH / SS ratio due to the influence of the composition is considered to be a positive effect, and the decrease was a negative effect. Is considered to be the effect of. In some patients the first administration of the formulation already had a positive effect, in others it required two or more doses. More often, the optimal biological response to IFN is dose 400
, 200 and 100 IU / ml of blood and Ukrain at doses of 0.5, 0.1 and 0.2 μg / ml of blood. A standardized therapeutic IFN dose of 600 to 1000 IU / ml corresponding to a 3.0 to 5.0 MU dose in vivo injection showed a positive effect on the SH / SS system only in 0 to 18.2% cases, 6
Negative effects were shown in 3.6 to 81.8% of cases, which is one of the reasons for the poor effect of IFN on CHC and frequent side effects in IFN treatment. Almost half of all CHC patients are resistant to IFN (47.5%), including four cases with a proven HCV phenotype Ib. After individual treatment with IFN or Ukrain, 9 out of 10 patients received HCV-in PCR.
It was RNA negative. The breakdown was 3 months later, 3 patients treated with a single IFN dose 3
3 months later and 3 weeks after monotherapy with Ukrain. No serious side effects were observed and all patients continue to be treated.
【0012】
得られたこれらのデータをもとに、特定の最適な用量のIFNまたはウクライ
ンでの治療から利益を得られる患者と、これに応答せず、異なる薬剤で治療すべ
き患者とを治療前選択するための方法を提供することができた。単独治療はCH
C治療の効率を高め、副作用の数を減らし、治療のコスト効率を高める(例えば
、IFN治療のコストが1/3から1/5になる)。Based on these data obtained, it is possible to treat patients who would benefit from treatment with a specific optimal dose of IFN or Ukrain and those patients who do not respond to this and should be treated with different drugs. A method for pre-selection could be provided. Single treatment is CH
Increase the efficiency of C treatment, reduce the number of side effects, and increase the cost efficiency of treatment (for example, the cost of IFN treatment decreases from 1/3 to 1/5).
【0013】
2.ウクライン(Ukrain)単独の使用
方法
血液のチオール−ジスルフィド比(SH/SS)(ロシア連邦特許21507
00号)でのウクラインの効果(クサノオウ−アルカロイドおよびチオリン酸ト
リアジリジドの半合成化合物、NSC−631570、「Nowicky Ph
arma」、オーストリア)をインビトロで、電流滴定法により試験した。CH
C患者26人を検査した。ウクラインを用量0.05、0.1、0.2、0.5
、1.0および2.0μg/血液mlで試験した。個々に最適な用量のウクライ
ン(注射1回あたり0.25から2.5mg)を用いる臨床パイロット試験のた
めに、隔日にCHC患者4人(未治療の患者2人ならびに当初、インターフェロ
ン−αで治療されたが失敗している証明HCV表現型lbに苦しむ患者2人)を
選択した。2. Method of Using Ukrain Alone Thiol-disulfide ratio (SH / SS) of blood (Russian Patent 21507)
No. 00) effect of Ukrain (semi-synthetic compound of celandine-alkaloid and thiophosphoric acid triaziridide, NSC-63570, "Nowicky Ph
arma ", Austria) was tested in vitro by amperometric titration. CH
Twenty-six C patients were examined. Ukrain dose 0.05, 0.1, 0.2, 0.5
, 1.0 and 2.0 μg / ml blood. 4 CHC patients (2 untreated and initially treated with interferon-α every other day for clinical pilot studies with individually optimized doses of Ukrain (0.25 to 2.5 mg per injection). (2 patients suffering from the proven HCV phenotype Ib) who were successful but failed.
【0014】
ウクラインに対する反応は様々であることが証明された。患者全員のうち73
.1%はこの組成物に対して感受性があったが、CHC患者の同じグループでイ
ンターフェロンα2b(IFN)に対する感受性はかなり低い、すなわち46.2
%であった。IFN耐性なCHC患者の群では、ウクラインに対する感受性はほ
ぼ等しく(71.4%)、さらにHCV表現形lbに苦しんでいるCHC患者の
4人全員がインビトロでウクラインに対して感受性があった。往々にして、最適
な生物学的応答はウクライン用量0.5、0.1および0.2μg/血液mlで
観察された。臨床試験では、プラスの臨床生化学的応答(4つのケース全てでA
LT(アラニントランスアミナーゼ)の低下)およびウイルス応答(PCR H
CV−RNAが3つのケースでマイナスであり、HCVlbを伴うケース1つを
含む)がすでに10回のウクライン注射の後に見ることができた。2つのケース
では、ウクライン治療開始後のALTの上昇が、ALTの低下に先立った(HC
Vlbを伴う他の1つのケースを含み、その例ではALTは1/3以上低下した
)。ウクライン治療後に血清SH/SS比が生化学的およびウイルス応答を伴う
3つのケースで上昇し、ウイルス応答を伴わないケースでは低下した。副作用は
観察されなかった。これら4人の患者の治療を継続する。It has been demonstrated that the response to Ukrain varies. 73 of all patients
. 1% were sensitive to this composition, but much less sensitive to interferon α 2b (IFN) in the same group of CHC patients, ie 46.2.
%Met. In the group of IFC-resistant CHC patients, susceptibility to Ukrain was approximately equal (71.4%), and further, all four CHC patients suffering from the HCV phenotype lb were susceptible to Ukrain in vitro. Optimal biological responses were often observed at Ukrain doses of 0.5, 0.1 and 0.2 μg / ml blood. In clinical trials, a positive clinical biochemical response (A in all four cases)
Decrease in LT (alanine transaminase) and viral response (PCR H
CV-RNA was negative in 3 cases, including 1 case with HCV lb) could already be seen after 10 Ukrain injections. In two cases, increased ALT after initiation of Ukrain treatment preceded decreased ALT (HC
Included one other case with Vlb, in which case ALT was reduced by more than 1/3). After Ukrain treatment, the serum SH / SS ratio was increased in 3 cases with biochemical and viral response and decreased in the case without viral response. No side effects were observed. Continue treatment of these 4 patients.
【0015】
ウクラインに対するCHC患者の高い応答率がインビトロで決定され(IFN
より1.58倍高い)、ウクラインおよびIFNとの間に交叉耐性は存在しない
。HCV表現型lbに苦しんでいる患者でさえもインビトロおよびインビボの両
方でウクラインに対して感受性がある。ウクラインによるCHCの個別治療は、
まだ治療を受けていない患者や、また耐性がある、あるいはIFN単独またはリ
バビリン(Ribabirin)と組み合わせたIFN後に再発を示す患者の両
方に有効であると考えられる。これらの結果に基づき、CHC患者を治療するた
めに、ウクラインを用いて特別な臨床試験を開始することができる。The high response rate of CHC patients to Ukrain was determined in vitro (IFN
1.58 times higher), there is no cross-resistance with Ukrain and IFN. Even patients suffering from the HCV phenotype lb are susceptible to Ukrain both in vitro and in vivo. Individual treatment of CHC by Ukrain
It is believed to be effective both in patients who have not yet been treated, and also in patients who are resistant or who have relapses after IFN alone or in combination with ribavirin. Based on these results, special clinical trials can be initiated with Ukrain to treat CHC patients.
【0016】
本発明により調製される薬剤は好ましくは、場合によりそれ自体公知の補助物
質とさらに組み合わせて使用するアルカロイドのリン誘導体またはその塩の水溶
液を含む。本発明による薬剤は好ましくは注射、例えば腹腔内、筋肉内又は静脈
内に投与され、用量は治療すべき疾患の重度、さらに患者の状態に依存および関
連する。The medicaments prepared according to the invention preferably comprise an aqueous solution of a phosphorus derivative of the alkaloid, or a salt thereof, optionally in further combination with auxiliary substances known per se. The agents according to the invention are preferably administered by injection, eg intraperitoneally, intramuscularly or intravenously, the dose depending on and related to the severity of the disease to be treated and also the condition of the patient.
【0017】
しかし、場合に応じて適切な用量を決定することは、治療を実施する医師の専
門知識の範囲内である。However, it is within the expertise of the treating physician to determine the appropriate dose in any given case.
───────────────────────────────────────────────────── フロントページの続き (81)指定国 EP(AT,BE,CH,CY, DE,DK,ES,FI,FR,GB,GR,IE,I T,LU,MC,NL,PT,SE,TR),OA(BF ,BJ,CF,CG,CI,CM,GA,GN,GW, ML,MR,NE,SN,TD,TG),AP(GH,G M,KE,LS,MW,MZ,SD,SL,SZ,TZ ,UG,ZW),EA(AM,AZ,BY,KG,KZ, MD,RU,TJ,TM),AE,AG,AL,AM, AT,AU,AZ,BA,BB,BG,BR,BY,B Z,CA,CH,CN,CO,CR,CU,CZ,DE ,DK,DM,DZ,EE,ES,FI,GB,GD, GE,GH,GM,HR,HU,ID,IL,IN,I S,JP,KE,KG,KP,KR,KZ,LC,LK ,LR,LS,LT,LU,LV,MA,MD,MG, MK,MN,MW,MX,MZ,NO,NZ,PL,P T,RO,RU,SD,SE,SG,SI,SK,SL ,TJ,TM,TR,TT,TZ,UA,UG,US, UZ,VN,YU,ZA,ZW─────────────────────────────────────────────────── ─── Continued front page (81) Designated countries EP (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, I T, LU, MC, NL, PT, SE, TR), OA (BF , BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG), AP (GH, G M, KE, LS, MW, MZ, SD, SL, SZ, TZ , UG, ZW), EA (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, B Z, CA, CH, CN, CO, CR, CU, CZ, DE , DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, I S, JP, KE, KG, KP, KR, KZ, LC, LK , LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, P T, RO, RU, SD, SE, SG, SI, SK, SL , TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
Claims (2)
ウのアルカロイドとチオリン酸トリアジリジドとの反応生成物の使用。1. Use of a reaction product of an alkaloid of Xanthomonas and thiophosphoric acid triaziridide for producing a drug for treating hepatitis C.
に使用することを特徴とする、請求項1に記載の使用。2. Use according to claim 1, characterized in that the reaction product is used together with other active substances, in particular interferon-α.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT481/2000 | 2000-03-22 | ||
AT0048100A AT408719B (en) | 2000-03-22 | 2000-03-22 | AGENT FOR TREATING HEPATITIS C |
PCT/AT2001/000076 WO2001070203A2 (en) | 2000-03-22 | 2001-03-20 | Agent for treating hepatitis c containing ukrain |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2003527414A true JP2003527414A (en) | 2003-09-16 |
Family
ID=3674939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001568401A Pending JP2003527414A (en) | 2000-03-22 | 2001-03-20 | Drugs for treating hepatitis C |
Country Status (17)
Country | Link |
---|---|
JP (1) | JP2003527414A (en) |
KR (1) | KR20020087045A (en) |
CN (1) | CN1416347A (en) |
AT (1) | AT408719B (en) |
AU (1) | AU2001239000A1 (en) |
BG (1) | BG107088A (en) |
BR (1) | BR0107211A (en) |
CA (1) | CA2389173A1 (en) |
EA (1) | EA200200584A1 (en) |
HR (1) | HRP20020367A2 (en) |
IL (1) | IL149314A0 (en) |
IS (1) | IS6360A (en) |
MA (1) | MA25509A1 (en) |
MX (1) | MXPA02004993A (en) |
NO (1) | NO20022253L (en) |
PL (1) | PL365000A1 (en) |
WO (1) | WO2001070203A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106343303A (en) * | 2015-07-13 | 2017-01-25 | 张如安 | Beverage for killing hepatitis B virus |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH695417A5 (en) * | 2001-11-15 | 2006-05-15 | Ddr Wassyl Nowicky Dipl Ing | Process for reacting alkaloids. |
EP1459753A1 (en) | 2003-03-18 | 2004-09-22 | Nowicky, Wassyl, Dipl.-Ing. DDr. | Quaternary chelidonine and alkaloid derivatives, process for their preparation and their use in the manufacture of medicaments |
CA2664935A1 (en) * | 2006-09-26 | 2008-04-03 | Addiction Research Institute, Inc. | Compositions for the treatment of hepatitis c and methods for using compositions for the treatment of hepatitis c |
CN106109538A (en) * | 2016-07-29 | 2016-11-16 | 桂林淮安天然保健品开发有限公司 | The pharmaceutical composition for the treatment of hepatitis C |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3128018A1 (en) * | 1981-07-13 | 1983-04-07 | Wassyl 1060 Wien Nowicky | "METHOD FOR DIAGNOSTICING AND FOR THE THERAPEUTIC TREATMENT OF TUMORS AND / OR INFECTIOUS DISEASES OF DIFFERENT TYPES WITH PREPARATIVE USE OF ALKALOID COMPOUNDS OR THEIR SALTS" |
US4816462A (en) * | 1982-05-18 | 1989-03-28 | Nowicky Wassili | Method for diagnosing and for the therapeutic treatment of tumors and/or infectious diseases of different types with alkaloid-compounds |
US4970212A (en) * | 1982-05-18 | 1990-11-13 | Nowicky Wassili | Method of treating human illnesses which compromise the ability to mount an effective immunological response |
PT93772A (en) * | 1989-04-17 | 1991-01-08 | Searle & Co | PROCESS FOR THE PREPARATION OF COMPOSITIONS FOR THE TREATMENT OF NEOPLASMS, CONTAINING AN ANTI-NEOPLASTIC AGENT, FOR EXAMPLE DOXORUBICIN AND A PROTEIN AGENT TO REDUCE THE SIDE EFFECTS, FOR EXAMPLE CARBETIMER |
-
2000
- 2000-03-22 AT AT0048100A patent/AT408719B/en not_active IP Right Cessation
-
2001
- 2001-03-20 KR KR1020027005739A patent/KR20020087045A/en not_active Application Discontinuation
- 2001-03-20 BR BR0107211-0A patent/BR0107211A/en not_active IP Right Cessation
- 2001-03-20 CN CN01803046A patent/CN1416347A/en active Pending
- 2001-03-20 AU AU2001239000A patent/AU2001239000A1/en not_active Abandoned
- 2001-03-20 JP JP2001568401A patent/JP2003527414A/en active Pending
- 2001-03-20 CA CA002389173A patent/CA2389173A1/en not_active Abandoned
- 2001-03-20 WO PCT/AT2001/000076 patent/WO2001070203A2/en active Application Filing
- 2001-03-20 MX MXPA02004993A patent/MXPA02004993A/en unknown
- 2001-03-20 IL IL14931401A patent/IL149314A0/en unknown
- 2001-03-20 EA EA200200584A patent/EA200200584A1/en unknown
- 2001-03-20 PL PL01365000A patent/PL365000A1/en not_active Application Discontinuation
-
2002
- 2002-04-24 IS IS6360A patent/IS6360A/en unknown
- 2002-04-26 HR HR20020367A patent/HRP20020367A2/en not_active Application Discontinuation
- 2002-05-10 NO NO20022253A patent/NO20022253L/en unknown
- 2002-05-28 MA MA26657A patent/MA25509A1/en unknown
- 2002-09-12 BG BG107088A patent/BG107088A/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106343303A (en) * | 2015-07-13 | 2017-01-25 | 张如安 | Beverage for killing hepatitis B virus |
Also Published As
Publication number | Publication date |
---|---|
WO2001070203A2 (en) | 2001-09-27 |
BR0107211A (en) | 2004-01-06 |
MXPA02004993A (en) | 2003-10-14 |
IL149314A0 (en) | 2002-11-10 |
CN1416347A (en) | 2003-05-07 |
AU2001239000A1 (en) | 2001-10-03 |
BG107088A (en) | 2003-05-30 |
PL365000A1 (en) | 2004-12-27 |
CA2389173A1 (en) | 2001-09-27 |
HRP20020367A2 (en) | 2004-02-29 |
ATA4812000A (en) | 2001-07-15 |
NO20022253D0 (en) | 2002-05-10 |
NO20022253L (en) | 2002-05-10 |
KR20020087045A (en) | 2002-11-21 |
EA200200584A1 (en) | 2003-06-26 |
AT408719B (en) | 2002-02-25 |
WO2001070203A3 (en) | 2002-09-06 |
IS6360A (en) | 2002-04-24 |
MA25509A1 (en) | 2002-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU750026B2 (en) | Product comprising at least a double stranded RNA combined with at least an antiviral agent | |
JP5539363B2 (en) | Combination of HCV NS3 protease inhibitors with interferon and ribavirin | |
JP2009502920A5 (en) | ||
JP2002539244A (en) | Composition for promoting growth | |
JP2010070566A (en) | Viral hepatitis treatment | |
KR20050055053A (en) | Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c | |
JP2009522371A5 (en) | ||
US20100266590A1 (en) | Combination therapy | |
JP2018531945A (en) | Use of peptides to stimulate the immune system | |
TW201138773A (en) | Dosage regimens for HCV combination therapy | |
JP2002527522A (en) | Ribavirin-interferon-α combination therapy for detectable HCV-RNA eradication in patients with chronic hepatitis C infection | |
JP2007262082A (en) | Use of riluzole for treatment of multiple sclerosis | |
JP2003527414A (en) | Drugs for treating hepatitis C | |
JP2003507339A (en) | Mycophenolate mofetil in combination with PEG-IFN-α | |
WO2021231941A1 (en) | Tlr7/8 antagonists for the treatment of coronavirus infections | |
JP2002525333A (en) | Treatment of hepatitis B virus with lamivudine or thymosin-alpha 1 in combination with lamivudine and fanciclovir | |
JP2003503457A (en) | Use of an angiotensin II type 1 receptor antagonist in the manufacture of a medicament for treating cardiovascular complications | |
JP2003522121A (en) | Use of riluzole for the treatment of multiple sclerosis | |
JP2003519088A (en) | Use of GSSG reductase for treatment and prevention of HIV infected patients | |
JP2000007578A (en) | Medication system for turning hepatitis c virus negative | |
WO2002011736A1 (en) | Naadp analogues for modulating t-cell activity | |
US7728033B2 (en) | Mycophenolate mofetil in diabetic nephropathy | |
IE921208A1 (en) | Complexes of polyadenylic acid with polyuridylic acid | |
KR20070053229A (en) | Compositions and methods for treating or preventing hepadnaviridae infection | |
KR20050101184A (en) | Hcv combination therapy |